William Blair downgraded MiNK Therapeutics (INKT) to Market Perform from Outperform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- MiNK data published showing complete remission, says H.C. Wainwright
- Promising Clinical Results and Positive Outlook for MiNK Therapeutics’ agenT-797 Drive Buy Rating
- Mink Therapeutics Inc trading resumes
- Mink Therapeutics Inc trading halted, volatility trading pause
- Why Is MiNK Therapeutics Stock (INKT) Up 190% Today?